Last updated 2026-09-04
- Went public on Nasdaq (ICCM), Aug 2021
- Raised $10M Follow-on PO, Jul 2025
- Raised $14M Follow-on PO, Jan 2025
Total raised
$53.0M
Last: PIPE 2026-06
Stage
Public
Founded
2006
Headcount
84
HQ
Caesarea, Israel
Sector
Medical Devices
About
IceCure Medical is a commercial-stage medical device company focused on transforming healthcare by providing minimally invasive cryoablation treatment options for benign and malignant tumors. Their flagship product, the ProSense® Cryoablation System, uses liquid nitrogen to destroy tumors by freezing them, offering an alternative to surgical removal for various indications including breast, kidney, bone, and lung cancer. The company emphasizes empowering patients with treatment choices and providing a safe, effective, and convenient outpatient procedure with minimal scarring. IceCure Medical's technology is supported by clinical data and has regulatory approvals worldwide.
Funding history · 5 rounds · $53.0M total
9 events/rounds · $53.0M Total Funding: $77.0M in Public Equity
May 2026
Follow-on PO
$4.3M
Jul 2025
Follow-on PO
$10.0M
Jan 2025
Follow-on PO
$14.0M
Jan 2024
Follow-on PO
$9.7M
Dec 2021
Follow-on PO
$15.0M
Headcount over time
84 employees (2026-09) · 1 point
Offices
Caesarea, Israel · HQ / main office
Show all offices (1 more)
- Nanuet, United States
Q&A
- What is IceCure Medical's primary business?
- IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of benign and malignant tumors by freezing them. Their flagship product is the ProSense® Cryoablation System.
- When did IceCure Medical go public on NASDAQ?
- IceCure Medical went public on NASDAQ in August 2021.
- What was the amount raised in IceCure Medical's most recent public offering?
- In May 2026, IceCure Medical raised $4,339,697 in a Public Offering.
- What was a significant regulatory approval for IceCure Medical in July 2024?
- In July 2024, the U.S. Food and Drug Administration granted regulatory clearance to IceCure for its next-generation XSense™ Cryoablation System with CryoProbes.
- What were the key findings from IceCure's ICE3 clinical trial for breast cancer?
- In September 2024, the 5-year results from IceCure's ICE3 trial, published in the Annals of Surgical Oncology Journal, demonstrated a 96.3% recurrence-free rate for early-stage, low-risk breast cancer patients who underwent ProSense cryoablation with endocrine therapy.
- What was the outcome of the FDA advisory panel meeting for ProSense® in November 2024?
- In November 2024, an FDA advisory panel voted favorably on the benefit-risk profile of IceCure's ProSense® cryoablation system for early-stage, low-risk breast cancer.
- What was a significant patent allowance IceCure Medical received in October 2024?
- In October 2024, IceCure received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation cryoablation system.
- What was the outcome of the ICESECRET study for kidney tumors, as reported in May 2026?
- In May 2026, data presented at ECIO 2026 from the ICESECRET study showed IceCure's ProSense® cryoablation system to be safe and effective in the destruction of kidney tumors with an 89.4% recurrence-free rate.
- What was a notable development regarding IceCure Medical's Nasdaq compliance in June 2026?
- In June 2026, IceCure Medical announced a 1-for-30 reverse share split to support Nasdaq compliance.
- What was the reported sales growth for ProSense® in North America in IceCure Medical's 2024 financial results?
- In March 2025, IceCure Medical reported 42% growth in ProSense® cryoablation sales in North America for its 2024 financial results.
Team · 8
Eyal Shamir
CEO
Meir Peleg
CFO
Shay Levav
COO
Tlalit Bussi Tel-Tzure
VP Business Development & Global Marketing
Merav Nir Dotan
VP Human Resources
Shad Good
VP Sales North America
Ron Mayron
Chairman of the Board
Ronen Tsimerman
Company Secretary
Sectors & technology
Primary sector
Medical Devices
Technologies
Target customers
Business model
B2BB2C
Highlights
1 PatentsVerified
Tags
femtechminimally-invasivemedical-deviceswomen-healthultrasoundhospitalssurgeonsradiologyoncologybiopsycancerhealthcare-providerswomenclinicscancer-therapytreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | IceCure Medical Ltd. |
|---|---|
| Founded | 2006 |
| Employees (exact) | 84 |
| Offices | Nanuet |
| Market cap | $42.1M |
| Status reason | Public on TASE on Feb 2011;Public on NASDAQ on Aug 2021; |
| Wikidata QID | Q115792001 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2021-08 | Nasdaq | ICCM | |
| Public Offering | 2022-12 | Nasdaq | ICCM | $14.5M |
| Registered Direct Offering | 2026-03 | Nasdaq | ICCM | $4.0M |
| Private Placement | 2026-06 | Nasdaq | ICCM | $5.5M |
Radar intelligence
Patents
| EPO | 20 |
|---|
Web history (Wayback)
| Domain | icecure-medical.com |
|---|
Wikidata
| QID | Q115792001 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513787804 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2006-01-25 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | האשל 7 קיסריה |